Medicare Advantage, Medigap, and Part D plan design, network and rate changes, plan exits, prior authorization, and prescription drug coverage shifts.

Medicare Advantage and Part D Market Changes

The Medicare landscape continues to undergo profound changes as 2027 approaches, marked by escalating complexities in Medicare Advantage (MA), Medigap (Medicare Supplement), and Part D prescription drug plans. Recent developments—including widespread Medicare Advantage plan exits and network contractions, regulatory proposals increasing cost-sharing and prior authorization, and ongoing volatility in Part D coverage and premiums—underscore the critical need for beneficiaries and advisors to remain vigilant, well-informed, and proactive.

Medicare Advantage and Medigap: Enduring Tradeoffs Amid Rising Disruptions

The fundamental tension between Medicare Advantage’s lower premiums with narrower networks and higher out-of-pocket costs versus Medigap’s higher premiums but predictable, broader coverage remains central to beneficiary decision-making. However, 2026–2027 data reveal increasing challenges that compound this classic tradeoff:

Forced disenrollments surged in 2026, with over 10% of MA enrollees losing their plans due to market exits, network narrowing, or benefit removals—a sharp rise from 6.9% in 2025. This has displaced millions, forcing many to reconsider Original Medicare with or without Medigap supplements.
Seven states experienced declines in MA enrollment, demonstrating that local market dynamics can sharply influence plan availability and network adequacy.
Meanwhile, Medigap offerings remain inconsistent, with state-dependent availability and premium spikes limiting options for some beneficiaries seeking to avoid MA’s uncertainties.

In response to beneficiary confusion about network breadth and access, CMS has launched a national Medicare Advantage provider directory covering hospitals and physicians, a significant transparency advance aimed at helping consumers compare plan networks before enrollment. Still, many enrollees face the challenge of losing long-standing providers and confronting unexpected out-of-pocket cost increases.

Advisors and advocates emphasize the critical importance of the Medicare Advantage Open Enrollment Period (January 1–March 31) as the primary window for displaced beneficiaries to switch plans or opt into Original Medicare and Medigap. Missing this window can leave beneficiaries with limited recourse until the next annual enrollment.

Regulatory Proposals and Rate Adjustments: Amplifying Cost Pressures and Administrative Hurdles

For 2027, CMS’s proposed Medicare Advantage benchmark increase of just 0.09% signals restrained growth in plan funding, which many experts argue will be insufficient to keep pace with healthcare inflation. The consequences may include:

Additional MA plan exits or benefit reductions.
Greater cost-sharing burdens for beneficiaries, particularly those with chronic conditions or higher healthcare utilization.

Moreover, two recent CMS proposals are poised to reshape the MA landscape by:

Potentially reducing covered benefits in certain plans.
Imposing higher copays and coinsurance for services, increasing financial barriers.
Expanding prior authorization requirements, adding layers of complexity and administrative burden for patients and providers alike.

These changes threaten to exacerbate the challenges already felt by beneficiaries navigating an increasingly restrictive MA market.

Medicare Part D: Navigating Formularies, Premium Volatility, and Coverage Expansions

The Part D prescription drug benefit remains a critical yet often confusing element of Medicare, with recent developments highlighting both progress and ongoing concerns:

CMS recently approved coverage of Wegovy (semaglutide) for patients with specific cardiovascular risk profiles, reflecting the program’s adaptation to emerging therapies and evolving clinical guidelines.
Despite the Inflation Reduction Act’s $2,100 hard cap on catastrophic drug spending (effective 2025), many beneficiaries face steep premiums and high deductibles, with some plans reporting year-over-year premium increases exceeding 100%.
The Government Accountability Office’s Medicare Part D Beneficiary Premium Stabilization Demonstration is underway, aiming to reduce premium volatility and enhance affordability, though its long-term impact remains uncertain.
The Part D late enrollment penalty continues to impose significant costs on beneficiaries who delay coverage without creditable drug insurance, making awareness and timely enrollment paramount. Appeals processes exist but require knowledge and advocacy to navigate effectively.

Expanding Prior Authorization: Growing Administrative Burdens and Access Challenges

CMS’s extension of prior authorization initiatives, such as Wisconsin’s WISeR program into Original Medicare, aims to improve cost control and appropriate utilization. However, these programs have introduced:

Delays in accessing medications and services, particularly problematic for chronic and complex conditions.
Increased administrative workload for beneficiaries and healthcare providers.
Heightened risks of treatment interruptions, disproportionately affecting vulnerable populations.

Experts call for CMS and plan sponsors to improve communication, simplify authorization procedures, and implement safeguards to prevent care disruptions.

Practical Guidance for Beneficiaries and Advisors

Given the rapidly shifting Medicare environment, beneficiaries and advisors should prioritize:

Annual, comprehensive plan reviews focusing on:
- Changes in MA provider networks and plan exits.
- State-specific Medigap plan availability and premium trends.
- Part D formulary updates, premium changes, and evolving prior authorization rules.
Timely action during enrollment periods, especially the Medicare Advantage Open Enrollment Period (Jan 1–Mar 31), to respond to forced disenrollments or benefit changes.
Careful Part D plan comparisons, with attention to formularies, cost-sharing, and penalty avoidance or appeal strategies.
Personalized tradeoff analyses balancing premiums, out-of-pocket expenses, provider access, and drug coverage aligned with individual health needs.
Staying informed about CMS regulatory proposals and advocacy developments to anticipate future changes.

New Resources to Aid Navigation

Beneficiaries and advisors can leverage newly available, actionable resources:

“How to Choose the Right Medicare Plan” by Jason Stolz offers a clear, comprehensive overview to guide plan selection strategies.
The YouTube video “The Medicare Drug Benefit Almost Nobody Knows About (But Should) | Part D Explained 2026” distills complex Part D concepts into a concise explainer, enhancing understanding of lesser-known benefits and enrollment nuances.

Media and Expert Perspectives

Recent media coverage and expert analyses have amplified awareness of these Medicare challenges:

Rodney Powell’s YouTube video “Medigap vs Advantage 🔔 Real Stories, Real Costs 🧑‍⚕️💰” provides candid, real-world insights into the cost and access tradeoffs beneficiaries face.
Reuters’ coverage titled “Millions of US Medicare Advantage Enrollees Forced to Switch Plans” highlights the growing scale and urgency of forced plan exits.
CMS’s launch of the national Medicare Advantage Directory of Hospitals and Physicians responds directly to beneficiary demand for greater transparency in network information.
The GAO’s ongoing work on the Part D Premium Stabilization Demonstration reflects federal efforts to tackle premium volatility and improve affordability.

Conclusion

As 2027 approaches, Medicare beneficiaries confront an increasingly complex and dynamic environment shaped by rising forced Medicare Advantage plan exits, narrowing networks, shifting regulatory landscapes, and evolving Part D drug coverage. The expansion of prior authorization programs adds administrative hurdles that further complicate access and continuity of care.

In this context, vigilance, education, and proactive plan management are essential. Beneficiaries and advisors must engage in thorough, personalized annual reviews; stay abreast of enrollment windows; and utilize new CMS tools and educational resources to optimize benefits and manage costs.

Ultimately, navigating the Medicare maze successfully demands a well-informed, adaptable strategy—one that balances premiums, provider access, drug coverage, and administrative realities in an era of ongoing transformation and uncertainty.

Sources (35)